Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
Acetates
/ administration & dosage
Adult
Aged
Cytomegalovirus
/ drug effects
Cytomegalovirus Infections
/ blood
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Male
Middle Aged
Quinazolines
/ administration & dosage
Transplantation, Homologous
/ adverse effects
Virus Replication
/ drug effects
Cytomegalovirus
allogeneic hematopoietic stem cell transplantation
letermovir
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
14
08
2020
revised:
27
08
2020
accepted:
28
08
2020
entrez:
29
9
2020
pubmed:
30
9
2020
medline:
8
10
2020
Statut:
ppublish
Résumé
Cytomegalovirus (CMV) replication may cause life-threatening complications after allogeneic haematopoietic stem cell transplantation (allo-HSCT). The aim of the study was to characterize CMV events, and the outcome of letermovir (LTV) CMV prophylaxis. In this retrospective analysis of patients treated with an allo-HSCT between 2010 and 2020, we determined plasma CMV events, as well as associated risk factors. We identified 423 patients who had undergone allo-HSCT between 2010 and 2020. CMV DNAemia was found in 130/423 (30.7%) of patients. CMV reactivation rate was significantly higher in patients with acute graft-versus-host disease, HLA mismatch, and CMV IgG seropositivity of donors and recipients. Among 42 patients receiving LTV prophylaxis those, 5 (11.9%) showed CMV DNAemia under LTV versus 87/353 (24.6%) in a control group. Despite the development of better approaches with weekly monitoring and early treatment initiation, CMV reactivations play an important role after allo-HSCT.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Cytomegalovirus (CMV) replication may cause life-threatening complications after allogeneic haematopoietic stem cell transplantation (allo-HSCT). The aim of the study was to characterize CMV events, and the outcome of letermovir (LTV) CMV prophylaxis.
PATIENTS AND METHODS
METHODS
In this retrospective analysis of patients treated with an allo-HSCT between 2010 and 2020, we determined plasma CMV events, as well as associated risk factors.
RESULTS
RESULTS
We identified 423 patients who had undergone allo-HSCT between 2010 and 2020. CMV DNAemia was found in 130/423 (30.7%) of patients. CMV reactivation rate was significantly higher in patients with acute graft-versus-host disease, HLA mismatch, and CMV IgG seropositivity of donors and recipients. Among 42 patients receiving LTV prophylaxis those, 5 (11.9%) showed CMV DNAemia under LTV versus 87/353 (24.6%) in a control group.
CONCLUSION
CONCLUSIONS
Despite the development of better approaches with weekly monitoring and early treatment initiation, CMV reactivations play an important role after allo-HSCT.
Identifiants
pubmed: 32988922
pii: 40/10/5909
doi: 10.21873/anticanres.14611
doi:
Substances chimiques
Acetates
0
Quinazolines
0
letermovir
1H09Y5WO1F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5909-5917Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.